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Geriatric Pharmacotherapy: Optimisation
Through Integrated Approach
in the Hospital Setting
Mirko Petrovic, Annemie Somers and Graziano Onder
Abstract Since older patients are more vulnerable to adverse drug-related events,
there is a need to ensure appropriate prescribing in these patients in order to prevent
misuse, overuse and underuse of drugs. Different tools and strategies have been
developed to reduce inappropriate prescribing; the available measures can be
divided into medication assessment tools, and speciﬁc interventions to reduce
inappropriate prescribing. Implicit criteria of inappropriate prescribing focus on
appropriate dosing, search for drug-drug interactions, and increase adherence.
Explicit criteria are consensus-based standards focusing on drugs and diseases and
include lists of drugs to avoid in general or lists combining drugs with clinical data.
These criteria take into consideration differences between patients, and stand for a
medication review, by using a systematic approach. Different types of interventions
exist in order to reduce inappropriate prescribing in older patients, such as: edu-
cational interventions, computerized decision support systems, pharmacist-based
interventions, and geriatric assessment. The effects of these interventions have been
studied, sometimes in a multifaceted approach combining different techniques, and
all types seem to have positive effects on appropriateness of prescribing.
Interdisciplinary teamwork within the integrative pharmaceutical care is important
for improving of outcomes and safety of drug therapy. The pharmaceutical care
process consists of four steps, which are cyclic for an individual patient. These steps
are pharmaceutical anamnesis, medication review, design and follow-up of a
pharmaceutical care plan. A standardized approach is necessary for the adequate
detection and evaluation of drug-related problems. Furthermore, it is clear that drug
therapy should be reviewed in-depth, by having full access to medical records,
laboratory values and nursing notes. Although clinical pharmacists perform the
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pharmaceutical care process to manage the patient’s drug therapy in every day
clinical practice, the physician takes the ultimate responsibility for the care of the
patient in close collaboration with nurses.
Keywords Geriatric pharmacotherapy  Optimization  Integrated approach
Introduction
Older individuals are more susceptible to adverse drug reactions (ADRs), which can
occur while they are hospitalized due to multiple comorbidities, the progression of
these conditions, the complexity of the therapeutic regimen or even drug-drug
interactions, but can also be the primary cause of hospitalization [1, 2]. While the
percentages of ADRs for all hospitalized patients vary between 2.4 and 10.9 % [3,
4], the incidence of ADRs is higher in older people as they take far more drugs than
younger individuals, the higher frequency being a common risk factor for the
development of ADRs. Therefore, it is of utmost importance that physicians to
understand the therapeutic schedule prescribed, the drugs being used by the patients
and the drug effects being experienced by the patients being submitted to the
hospital. However, obtaining accurate ﬁgures for older people is complicated by the
voluntary ADR reporting system in which it is known that under-counting is an
issue [5, 6]. Consequently, to avoid under-reporting, thought should be given to
combining information from physicians and nurses with data obtained directly from
the patient, perhaps via direct interview while staff members are making ward
rounds.
Although as a cause of hospital admissions, the percentage related to drug issues
varies considerably from 4 to 30 %, the majority are related to ADRs which are
considered avoidable in 50–97 % of the cases [7–9]. Moreover, while only 5.6 %
of the 13,000 unplanned hospital admissions analyzed in the prospective Hospital
Admissions Related to Medications study (HARM) were classiﬁed as drug-related,
the mean age of this population was signiﬁcantly higher compared to overall mean
population age, suggesting drug-related hospital admissions were more common in
older individuals [10].
It is also important to separate out the general factors responsible for the high
incidence of drug-related problems in older people [11–17], versus other factors
that further modulate the rate of ADRs in the hospital setting. In regard to the
former, it is common for older people to have many diseases at the same time that
may be treated with a variety of different drugs, which obviously increases the
complexity of the drug therapy for patients as well as the risk for adverse drug
events, including undesirable drug-drug interactions. Second, physiological and
biopharmaceutical changes in older people may be responsible for different phar-
macokinetic and pharmacodynamic proﬁle of drug products contributing to unan-
ticipated ADRs due to the lack of focus on the older and complex patient
populations in the clinical trial program during the development and marketing of
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the drug product. Another important consideration is the fact that, in an age in
which many older patients see several specialists in addition to and independently
from their primary care physicians, lack of coordination can increase the difﬁculty
to evaluate the overall medication schedule of the patient. This lack of coordination
can relate to indications for drug prescription, courses of therapies, the monitoring
of ADRs, and assessing drug effectiveness for the different medical problems for
which they were prescribed. Last but not least, older persons are also often chal-
lenged cognitively and physically to handle their medications (for example,
removing tablets or capsules from blister packs, or using inhalation devices
appropriately including the required inhalation techniques), which can results in
unsatisfactory compliance or inappropriate drug use and therapeutic outcomes.
Finally, it must be remembered that while older people are typically prescribed the
same drugs as younger adults often based on a “single disease” examination and
treatment view, many more drugs are being prescribed simultaneously (polyphar-
macy) with the possibility that some of the drugs may not exhibit the expected and
desired efﬁcacy and safety proﬁle [8–10].
In the hospital setting, older patients are often placed into acute geriatric wards.
But, despite good professional care that includes evidence-based pharmacotherapy,
inappropriate drug prescription still continues to occur thus elevating the risk of
ADRs [18–20]. The major reason is continuation of drug therapy initiated prior to
hospitalization plus additional drug prescription based on the acute treatment plan.
This practice gives rise to simultaneous administration of previously and newly
prescribed drugs without complete evaluation as to which drugs are really required,
should be continued, changed, temporarily or deﬁnitely stopped, as well as lacks the
necessary follow-up of the therapeutic effects and side-effects.
Designing strategies to prevent drug-related problems (DRPs) in older people
requires close attention to the associated factors in the hospital itself and incre-
mentally must address the transition between settings: admission to other hospitals
and discharge to the home or long-term care facilities. Consequently, admission to
the acute geriatric wards of a hospital affords both an opportunity to identify
patients at high risk for DRPs and evaluation of medication discrepancies that
already exist without compounding them further [21, 22].
Identiﬁcation of Older Patients at Risk for Developing
Adverse Drug Reactions
As a matter of fact, stafﬁng resources within hospitals are often limited particularly
when it comes to groups of individuals who need more attention than the ‘average’
patient. Consequently, within the multistep paradigm of geriatric pharmacotherapy,
the ﬁrst critical step is identiﬁcation of those older patients who are most at risk for
developing ADRs. This requires a continuous training of clinicians, nurses, and
pharmacists in recognizing ADRs, which in daily practice is unfortunately not
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achieved to the extend needed. Often an ADR is diagnosed and judged as a part of a
disease-related clinical symptom rather than a drug-related problem per se, which
may lead to further drug prescribing to control the ADR symptoms. In addition,
such ADRs are complicating the deﬁnition of the medical diagnosis and increasing
the chance for more drug-drug interactions, which, in turn, increases the odds that
more ADRs will occur in a phenomenon termed ‘the prescribing cascade’ [23].
Consequently, any differential diagnosis should always include the possibility that
presenting symptoms may be caused in part or wholly by an ongoing ADR. If a
high-risk patient can be identiﬁed at admission those patients will receive extra
attention from physicians, nurses, and pharmacists in regard to existing and new
medications that will beneﬁt most which in turn will mitigate the resource problem
—as well as lower the chance of avoidable ADR occurrences and prescription
cascading.
Two approaches have been recently reported in the literature which identify
older patients at high risk for developing ADRs, both of which are simple and
efﬁcient: the GerontoNet ADR risk score [24] and the Brighton Adverse Drug
Reactions Risk (BADRI) Model [25].
The GerontoNet risk score comprises those variables associated with ADRs and
includes: four or more comorbid conditions (1 point); heart failure (1 point); liver
disease (liver function test results that are more than twice the upper limit of
normal) (1 point); number of daily drugs (maximum 4 points for ≥8 drugs, 1 point
for 5–8 drugs, 0 points ≤5 drugs); previous ADRs (2 points); and renal failure
(estimated GFR <60 mL/min) (1 point). Within the score range of 0–10 points a
cut-off point of 3–4 presents a balance between optimal sensitivity (68 %) and
speciﬁcity (65 %) in classifying those patients most at risk for an ADR.
Although the GerontoNet ADR risk score is simple to use, not requiring any
clinical tests or complex biological parameters to be calculated, and can easily
classify patients according to risk, it still has limitations. For example, in an
observation study comprising 513 acutely ill patients aged ≥65 years, the
GerontoNet ADR risk score incorrectly classiﬁed 38 % of patients as low risk [26].
The alternative more recent approach to assess ADR risk is the BADRI model
[25], which is based on ﬁve clinical parameters with equal weighting: >8 drugs,
hyperlipidaemia, elevated white cell count, use of antidiabetic agents, and length of
hospital stay (>12 days). The best trade-off was found at a cut-off score of 1,
yielding a good sensitivity of 80 % but a poorer speciﬁcity of 55 %. A major
disadvantage of the BADRI model is that it requires length of the hospital stay in its
calculation, which means that the score will not be assessed until 12 days have
elapsed from initial admission. Validation results from European centres for both
approaches were similar, although the BADRI results reflect a higher patient age
and included possible ADRs rather than just deﬁnite and probable ADRs that were
used in construction of the GerontoNet ADR risk score. Thus, although a promising
start in this ﬁeld, this methodological assessment of risk patients for ADRs will
require further reﬁnement with the addition of other variables and perhaps
reweighting of its applicability and usability in routine practice where assessment of
ADRs and identiﬁcation of risk patents will have the highest impact. In addition,
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such approaches will gain better acceptability and implementation when the
assessment tools for ADRs will become more accurate.
Strategies to Reduce Inappropriate Drug Prescribing
in Older Patients
One obvious solution to reducing ADRs in older people in any kind of clinical
setting is to create a framework in which inappropriate drug prescribing is pre-
vented or at least diminished. Speciﬁc settings may require different sets and
combinations of interventions, explicit approaches include pharmacist-driven
interventions, educational interventions, and instruments to detect inappropriate
prescribing in older people, computerized decision support systems and geriatric
medical services interventions (Table 1).
Pharmacist-Driven Interventions
Traditionally, pharmacists just dispensed the drug products according to the pre-
scriptions. However, in the last 20 years there has been a gradual evolution towards
a patient-centred viewpoint in which pharmacists are taking increasing responsi-
bility for the drug therapy and welfare of their patients. Applying their speciﬁc
pharmaceutical expertise, clinical pharmacists contribute to the overall assurance
for the patient’s safety and effectiveness of the prescribed drugs [27]. This evolution
stems in part from a cyclical process applied each time a patient is prescribed a new
medication whereby the pharmacist will perform pharmaceutical anamnesis, med-
ication review, design of an individualized pharmaceutical care plan, and follow-up
of the plan [28].
This process is far from perfect in practice because it is assumed that someone—
the primary treating physician in most cases—actually takes responsibility for
working through the cycle elements based on available medical records, laboratory
values and nursing notes. Because electronic health records are not universally
available and certainly not linked between healthcare institutions, the available
information may be incomplete or even inaccurate, leading to erroneous conclu-
sions. Nevertheless, the ﬁrst step is identiﬁcation of all medications the patient is
taking, along with dosages, frequency, and route of administration. The second step
is to review the medications in the context of what is known about the patient
medically in a structured manner to identify inappropriate drug prescriptions taking
into account the patient’s limitations that could lead to misuse, overuse, underuse,
or medication errors. This process should lead to the identiﬁcation of possible
DRPs. Discussion with the patient and other physicians prescribing existing med-
ications should then take place so that a medication management plan can be
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generated to address any issues [29]. Finally, the pharmacist discusses with the
patient how the medications are best taken and the medication scheduled can be
implemented into the patient’s daily life.
Authors of a recent literature review concluded, that in general, pharmacother-
apy for older patients improved when pharmacists played a proactive role in per-
forming medication reviews and were involved in the active education of other
healthcare professionals. Nevertheless, a speciﬁc positive impact of pharmacists’
interventions on health outcomes, quality of life or cost-effectiveness could not
always be established [30]. Illustrative of this point is a randomized clinical trial
(RCT) investigating pharmacist-assisted medication reconciliation, inpatient
Table 1 Advantages and limitations of approaches to lower inappropriate drug prescribing
Approach Advantages Limitations
Pharmacist-driven
intervention
• Pharmacist has more in-depth
knowledge about drug adverse
effects that treating physician
• Can educate other healthcare
professionals
• Mixed/insufﬁcient evidence for
effect on health outcomes,
health related quality of life
and cost-effectiveness of care
• Working outside of the
multidisciplinary team often
fails
Educational
intervention
• Ongoing individualized,
interactive, multidisciplinary,
and multifaceted programs can
be helpful
• Need to deﬁne what is required
to assess adequacy for a given
level of intervention
• Mere dissemination of
guidelines unlikely to be
effective
Instruments to detect
inappropriate
prescribing in older
people
• Implicit: comprehensive and
systematic approach; includes
operational deﬁnitions, clear
instructions and examples;
good as an educational tool
• Explicit: relatively easy to
remember and to detect;
provide support to identify
inappropriate prescribing in
older people
• Implicit:
knowledge-dependent,
time-consuming and does not
assess underprescribing
• Explicit: time-consuming
unless process is automated
and the patient’s perspective is
often not taken into
consideration
Computerized
decision support
systems
• Have the potential to alert the
prescribing physician to
drug-prescribing issues
• Existing systems are not
geriatric speciﬁc; insufﬁcient
evidence for improvement in
patient outcomes; high volume
of alerts: risk of unimportant
warnings
Geriatric medical
services
interventions
• Integrated care and detailed
geriatric assessment can reduce
length of hospital stay and the
number of readmissions
• Pharmacotherapy must be part
of the initial geriatric
assessment for approach to
work well
• Heterogeneity in terms of
structural components and care
processes
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pharmacist counselling, low-literacy adherence aids, and individualized telephone
follow-up after hospital discharge. In the trial population of 851 adults hospitalized
for acute coronary syndromes or acute heart failure the per-patient number of
clinically important medication errors (incidence rate ratio, 0.92) or adverse drug
events (incidence rate ratio, 1.09) was not signiﬁcantly different between the
intervention and control groups [31]. The primary reason that the trial failed to
demonstrate any signiﬁcant effects could be seen in a lack of integration between
the pharmacists and other professional caregivers which is critical and was not
insufﬁciently addressed in the study. This was conﬁrmed by Spinewine et al. [30]
who noted that results of pharmacist-driven interventions tend to show better results
when pharmacists are skilled and work as part of a multidisciplinary team com-
posed of physicians, nurses and other caregivers. For example, in the RCT con-
ducted by Spinewine et al. [32] in which pharmaceutical care was delivered to
hospitalized older patients by an experienced clinical pharmacist who worked
contextually with the existing geriatric team, the results were superior in the
intervention arm compared to the control arm. Speciﬁcally, intervention subjects
experienced a signiﬁcant improvement in the appropriateness of prescribing from
hospital admission to discharge. In addition, when team-based care included
pharmacists, meta-analysis demonstrated that a 47 % reduction in adverse drug
events was possible [33].
These ﬁndings illustrate the complexity in globally assessing geriatric patients in
regard to appropriate pharmacotherapy and judgment of ADRs. The research also
suggests that isolated pharmacist-driven interventions are not likely to succeed;
rather, team-based approaches in which pharmacists are fully appraised in the
pharmacotherapy of older people are required. Finally, to better direct this kind of
research, larger multicentre trials are needed as sample sizes of available RCTs are
small [34–37].
Educational Interventions
Educational interventions of healthcare professionals vary broadly ranging from
teaching, interactive workshops, and face-to-face interactions to providing decision
algorithms. A systematic review of such interventions found mixed results [38] and
especially singled out limitations of several studies as they did not deﬁne what data
would be required to assess adequacy for a given level of intervention nor sample
size calculations to determine acceptable type I and type II errors. Another review
also suggested that mere dissemination of guidelines is unlikely to be effective,
whereas active educational interventions in the form of workshops, meetings, and
regular reports could improve drug treatment [39]. Taking together the results of the
studies clearly imply that ongoing individualized, interactive, multidisciplinary, and
multifaceted educational programs are a critical and important intervention to
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succeed in increasing awareness of healthcare professionals in regard to prescribing
medication in older patients.
Instruments to Detect Inappropriate Prescribing
in Older People
Several tools are available to clinicians to assess whether medication is appropriate
for older and multimorbid patients. These tools are either implicit, judgment-based,
instruments that include clinical information available about the patient or explicit,
criteria-based tools. The MAI is the most comprehensive and validated implicit tool
available to date. The MAI is based on ten elements of drug prescribing: indication,
effectiveness, dose, correct directions, practical directions, drug-drug interactions,
drug-disease interactions, duplication, duration, and cost. Summation of the ratings
produces a weighted score that is representative of whether prescribed drugs are
appropriate whereby lower scores are indicative as being more appro-
priate [40]. While straightforward, calculating the MAI score is time-consuming
and does not assess underprescribing. A study using adapted MAI scores found
considerable utility in detection of drug-related problems in geriatric inpatients and
was reliable with a low inter-rater variability as well as positive correlation between
high score and drug-related hospital admission [41].
Explicit tools, on the other hand, are consensus-based standards focusing on
drugs and diseases and include lists of drugs to avoid in general or lists combining
drugs with clinical data. Although many explicit tools have been developed over the
years [42–52], only the Beers criteria [53, 54] and Screening Tool of Older Persons’
Prescriptions (STOPP) [55, 56] criteria have been examined in terms of their pre-
dictive validity.
Almost 25 years ago, Beers and his coresearchers set about developing a list of
criteria using the Delphi approach that would lower the risk of drug prescribing in
older persons [53]. The Beers criteria have since undergone several updates, with
the latest revision in published in 2012 by the American Geriatrics Society using an
evidence-based approach that identiﬁes 53 drugs or drug classes divided into three
categories: potentially inappropriate drugs to avoid independent of comorbidities;
potentially inappropriate drugs to avoid in older adults with certain diseases and
syndromes because they might cause exacerbation, and medications to be used with
caution [54]. Based on the most recent criteria and using a community-dwelling
sample of U.S. older adults (N = 18,475). Davidoff et al. [57] estimated that the
potentially inappropriate medication (PIM) prevalence rate in the USA declined
from 45.5 % in 2006–2007 to 40.8 % in 2009–2010. While this is an encouraging
trend in the USA there is evidence that such criteria cannot be so easily applied in
European countries; for example, several drugs listed in the 2003 Beers criteria
were rarely prescribed or were not available in Europe and 2003 Beers-listed PIMs
were not associated with ADRs in some studies [58].
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Alternative tools initiated in 2008 and updated in 2015 termed STOPP
(Screening Tool of Older Person’s Prescription) and START (Screening Tool to
Alert doctors to Right—appropriate, indicated—Treatment), include potentially
inappropriate drugs (STOPP) as well as screening for omissions of indicated,
potentially beneﬁcial drugs (START) [55, 56]. The authors took a different
approach by organizing criteria according to physiological systems and include
both potentially inappropriate prescribing, and omission of potentially beneﬁcial
pharmacotherapy, which is missing from the Beers criteria. These START and
STOPP criteria have now been endorsed by the European Union Geriatric Medicine
Society (EUGMS). Perhaps what is most interesting about this approach is that their
application leads to signiﬁcant and durable improvements in the appropriateness of
prescribing at discharge and for up to 6 months after discharge, indicating that this
is a pragmatic tool capable of producing long-lasting, beneﬁcial effects for older
people [59, 60]. As an example of validation, a prospective study conducted
involving 600 consecutive inpatients aged 65 or more utilizing STOPP criteria
demonstrated an association with avoidable adverse drug events that cause or
contribute to urgent hospitalization, a result that could not be shown with the Beers
criteria [61].
Computerized Decision Support Systems
Another method to detect inappropriate drug prescribing and drug interactions and
reduce the risk of iatrogenic drug problems has been the ‘intelligent’ computerized
decision support system (CDSS). This is basically a series of algorithms imple-
mented through the use of specially designed software. Such algorithms are gen-
erally rule based. For example, based on known data about drugs in geriatric
populations upon a physician entry of a prescription order the software will check
whether the drug dosage is appropriate and whether it is contraindicated given the
patient’s comorbidities. Although the CDSS has the potential to alert the pre-
scribing physician to drug-prescribing issues, a recent review article concluded that
improvements in patient outcomes have not yet need established [62]. Part of the
reason for this is that physicians usually have the ability to override the system.
When a ‘hard stop’ is employed in conjunctions with computerize order entry this
could lead to a more effective system but could also delay critical patient medi-
cations [63]. Performance issues depend on how speciﬁc the information in the
system is as well as the system is by itself considering that if the system does not
recognize a geriatric patient, or impairments in individuals—for example, cognitive
deﬁcits—it will be of little use in older people as a means of stopping inappropriate
drug prescribing.
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Geriatric Medical Services Interventions
The use of multidisciplinary teams in medicine always confers advantages over
non-integrated healthcare providers within any system, and geriatrics is no
exception. When the medical and physiological complexity of older patients is
considered by the team prior to any pharmacotherapy, the risk of an ADR can be
lessened. Ideally, integrated medicine management is delivered starting with hos-
pital admission and following up after discharge in a manner that is transparent to
the patient with continuous information flow between hospital physicians and
nurses, clinical pharmacists inside or outside the hospital, and primary care
physicians. An ultimate patient beneﬁt is that this process leads to optimized drug
therapy with reduced length of hospital stay, longer time to readmission, and
decreases the number of readmissions [64].
The traditional medical approach to treatment of older patients, even within a
multidisciplinary framework, is not always enough to fully assess all problematic
areas. Therefore, a more comprehensive geriatric assessment may be required to
improve the pharmacotherapy and reduce the ADR rate. When this is done via the
production of an individual care plan tailored to an older person that includes a
more thorough evaluation it will result in enhanced care planning and better quality
of care [65]. In this process, the issue of pharmacotherapy is not seen as a separate
issue, but as part of the overall treatment plan, embracing a more holistic program
in which drug prescribing is one avenue of treatment that is integrated into others.
One further beneﬁt is that the drug prescription plan may be simpliﬁed based on
pharmacological and healthcare needs of the individual patient with concurrent
reductions in drug-related adverse events and increases in the quality of drug
prescribing [66–69]. In a large study employing a randomized 2 × 2 factorial
controlled design utilizing patients in 11 Veterans Affairs (VA) hospitals, inpatient
geriatric unit and outpatient geriatric clinic teams evaluated and managed patients
according to published guidelines and VA standards in the intervention arms [70].
A 35 % reduction in the risk of serious ADRs compared with usual care was
observed in outpatient geriatric clinic care and inpatient geriatric unit care with a
signiﬁcant reduction of unnecessary and inappropriate drug use and underuse.
Moreover, outpatient geriatric clinic care reduced the number of clinical conditions
that were caused by the omission of drugs signiﬁcantly.
In the context of comprehensive geriatric assessment, the CRIteria to assess
appropriate Medication use among Elderly complex patients (CRIME) project
generated 19 recommendations relating speciﬁcally to ﬁve chronic conditions
commonly experienced in older persons: diabetes, hypertension, congestive heart
failure, atrial ﬁbrillation and coronary heart disease. The intent of the project was to
make healthcare providers more aware that goals of treating older people in respect
of pharmacotherapy may be different from younger persons due to patient related
factors and the presence of conditions routinely experienced by this patient popu-
lation, such as limited life expectancy, functional and cognitive impairment and
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geriatric syndromes. These conditions frequently limit drug beneﬁts or can cause
negative outcomes in respect of drugs and need to be considered when prescribing
to such patients [71].
Conclusion
Single interventions as described in this review rarely achieve signiﬁcant enhanced
patient outcomes by themselves, but are far more effective when bundled together
in a rational and integrated fashion—for instance, the effectiveness of a medication
review by including a pharmacist in the context of a multidisciplinary team.
Approaching the subject of complex clinical and therapeutic problems of geriatric
patients with a global review that includes assessing each patient’s clinical and
functional parameters before tackling the pharmacological issues is likely to suc-
ceed better than merely reviewing pharmacotherapy by itself. If future clinical
research focuses on better integration of all methods with demonstrated improve-
ments in patient outcomes, more healthcare providers are likely to see the beneﬁts
of such approaches and adopt them.
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